Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

78 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-06-24

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim is to classify high grade glioma by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI). In order to provide more specific informations for the diagnosis and the prognosis of high grade glioma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

High Grade Glioma Proteomics MALDI-MSI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with grade III or IV glioma newly diagnosed with histological evidence
* Surgical indication
* Tumor tissue available at biobank of Lille
* Men and women aged ≥ 18 years
* Informed Consent signed by the patient or his legal representative.

Exclusion Criteria

* Antecedents of other cancers except basal cell skin cancer or carcinoma in situ of the uterus cervix
* Previous history of brain radiotherapy
* Anti-tumor systemic treatments (chemotherapy or targeted therapy) prior to surgery of glioma
* Genetic disease that may cause brain tumor, potentially radiation-induced tumor
* History of degenerative neurological disease prior to diagnosis
* contraindication to MRI

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emilie Le RHUN, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Lille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Le Rhun

Lille, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-A00185-42

Identifier Type: OTHER

Identifier Source: secondary_id

2013_27

Identifier Type: -

Identifier Source: org_study_id